Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies

Background: Data on convalescent plasma therapy (CPT) in patients of hematological malignancies with severe Covid-19 is scarce. Objective: To study 14-day mortality in patients who received CPT. Patients & methods: Retrospective multicentre observational study conducted in 4 centres treating haematological malignancies across Delhi-national capital region. Total 33 haematological malignancies patients with severe Covid-19 who received CPT were analysed. Results: The median age of the study cohort was 62 years (18-80 years). Twenty one percent patients had 1 comorbidity, 18 % had 2 comorbidities and 6% patients had 3 and 5 comorbidities each. Twenty four patients were on active therapy. Sixty nine percent of patients required ICU stay. Twenty five patients received plasma therapy within 7 days (early) of diagnosis of Covid-19 infection. Median day of plasma infusion from date of diagnosis of Covid-19 infection was 4 days (range: 2-25 days). Patient who had early initiation of plasma therapy had shorter duration of hospitalisation (12.7 vs 24.3 days, p = 0.000). Overall mortality in the cohort was 45.5%. There was no effect of disease status, active therapy, presence of comorbidity on mortality. There was no difference in the mortality in patients receiving early vs late initiation of plasma therapy or in patients receiving one versus two plasma therapy. Conclusions: We provide a large series of patients with hematological malignancies and role of CPT in this group.

Automated summary

This retrospective multicentre study analyzed the 14-day mortality in 33 patients with hematological malignancies who received convalescent plasma therapy for severe Covid-19. The study found that patients who received plasma therapy early had a shorter duration of hospitalization. The overall mortality rate was 45.5%, with no significant impact of disease status, active therapy, or comorbidities on mortality.